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Background: Accumulating evidence supports cancer to initiate and develop from a small population of stem-like
cells termed as cancer stem cells (CSC). The exact phenotype of CSC and their counterparts in normal mammary gland
is not well characterized. In this study our aim was to evaluate the phenotype and function of stem/progenitor cells in
normal mammary epithelial cell populations and their malignant counterparts.
Methods: Freshly isolated cells from both normal and malignant human breasts were sorted using 13 widely used
stem/progenitor cell markers individually or in combination by multi-parametric (up to 9 colors) cell sorting. The sorted
populations were functionally evaluated by their ability to form colonies and mammospheres, in vitro.
Results: We have compared, for the first time, the stem/progenitor markers of normal and malignant breasts side-by-side.
Amongst all markers tested, we found CD44high/CD24low cell surface marker combination to be the most efficient at
selecting normal epithelial progenitors. Further fractionation of CD44high/CD24low positive cells showed that this
phenotype selects for luminal progenitors within Ep-CAMhigh/CD49f + cells, and enriches for basal progenitors within
Ep-CAM-/low/CD49f + cells. On the other hand, primary breast cancer samples, which were mainly luminal Ep-CAMhigh,
had CD44high/CD24low cells among both CD49fneg and CD49f + cancer cell fractions. However, functionally, CSC were
predominantly CD49f + proposing the use of CD44high/CD24low in combination with Ep-CAM/CD49f cell surface
markers to further enrich for CSC.
Conclusion: Our study clearly demonstrates that both normal and malignant breast cells with the CD44high/CD24low
phenotype have the highest stem/progenitor cell ability when used in combination with Ep-CAM/CD49f reference
markers. We believe that this extensive characterization study will help in understanding breast cancer carcinogenesis,
heterogeneity and drug resistance.
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Breast cancer is the most common cancer in women and,
despite various treatment regimens, many patients die
from the disease. A subpopulation of tumor cells, called
cancer stem cells (CSC), is believed to contribute to the
failure of breast cancer therapy due to their reported
resistance to chemotherapy [1,2] and radiotherapy [3].
Due to their self-renewal abilities, even a minute popula-
tion of CSC can form tumor when isolated and injected
into an appropriate mouse model, while the remaining
cells fail to do so [4]. Breast CSC have been characterized
as CD44high/CD24low [5], or aldehyde dehydrogenase
enzyme (ALDH)high [6]. However, how CSC relate to the
different stem/progenitor cell populations of normal hu-
man mammary gland and whether CSC arise from normal
mammary stem/progenitor or even differentiated cells,
remains unanswered [4].
The normal mammary gland epithelium is composed
of two types of epithelial cells: 1) basal contractile cells
(mostly myoepithelial) that are in direct contact with the
basement membrane and, 2) secretory luminal cells that
face the lumen of ducts/lobules. The phenotype of the nor-
mal human mammary gland stem/progenitor cells has
been described in various reports as being aldehyde de-
hydrogenase (ALDH)high [6], CD10+ [7,8], CD44highCD24low
[5] or Ep-CAM+/MUC-1neg [9]. Additionally, two other
markers have become a standard combination for studying
human normal mammary gland cells: EP-CAM (epithelial
specific antigen, ESA) and CD49f (α-6-integrin) [10]. Previ-
ous reports indicate that Ep-CAMhigh labels luminal epithe-
lial cells where the Ep-CAMhigh/CD49f + fraction contains
the luminal progenitors, while Ep-CAMhigh/CD49fneg cells
represent the differentiated luminal cells. On the other
hand, Ep-CAM-/low/CD49f + phenotype characterize mainly
the basal fraction of the human epithelial cells [8,11].
Whether the aforementioned stem/progenitor cell markers,
described in different reports, identify overlapping cell
populations and whether they are related to CSC re-
mains unknown.
In this study, we demonstrated that human mammary
epithelial cells with CD44high/CD24low phenotype have the
highest progenitor ability compared to all other stem/
progenitor subpopulations. Furthermore, we have dem-
onstrated that, in both normal and malignant breasts,
there are multiple CD44high/CD24low subpopulations. In
the majority of breast cancer cases, CSC with CD44high/
CD24low phenotype existed in the Ep-CAMhigh/CD49f +
fraction of cancer cells. Stem/progenitor markers should
be used in combination with Ep-CAM/CD49f reference
markers to indicate the pure/specific epithelial stem/
progenitor cells. We believe this study may provide a
better understanding of breast cancer carcinogenesis
as well as facilitate the more accurate identification
of CSC. Subsequently, these findings might help inmonitoring and/or targeting of this population in
the future.
Methods and materials
Patient selection and consenting
This study was conducted in accordance with the Helsinki
Declaration and approved by the Research Advisory Coun-
cil (RAC# 2080-045) of King Faisal Specialist Hospital and
Research Centre (KFSH&RC). Normal human mammary
gland tissues were obtained from 16 patients admitted to
KFSH&RC who underwent reduction mammoplasty with
no previous history of breast cancer. Breast cancer samples
were obtained from 16 patients diagnosed with invasive
ductal carcinoma of the breast (cases were ER + (n = 5),
ER/Her2 (n = 3), Her2 (n = 3) and basal tumors (n = 5)
ER = ER+/PR+/Her2neg, ER/Her2 = ER+/PR + orneg/Her2+,
Her2 = ERneg/PRneg/Her2+, and basal = ERneg/PRneg/Her2neg).
All patients signed an informed consent approved by
KFSH&RC.
Tissue processing and cell preparation
Processing of breast cancer tissues was performed after
routine pathological examination. Gross tissue specimens
were macro-dissected by pathologist and frozen sections
were examined by hematoxylin staining to ensure that
they contained carcinoma cells. Breast tissues (plastic
surgery or breast cancer) were kept at 4°C in complete
medium, (DMEM medium with 10% fetal bovine serum
(FBS)) and processed within 1-2 hours. Tissues were
minced, transferred to collagenase digestion medium
(Stem Cell Technologies (SCT), Vancouver, Canada) and
agitated with an Adams Nutator Mixer (Becton Dickinson,
Franklin Lakes, NJ) at 37°C.
Normal Tissue pieces were digested overnight and cell
suspensions were centrifuged at 800 g for 8 minutes at
4°C. Fat was aspirated and cell pellets were re-suspended
in phosphate buffered saline (PBS). Cells were differentially
centrifuged at 120 g for 2 minutes at 4°C to enrich for
epithelial cells. The epithelial-enriched pellet was further
digested with accutase (SCT) at 37°C (30-60 minutes)
until organoids disaggregated into single cells. Epithelial
cells were washed once with medium or PBS, filtered
through a 70 μm mesh (BD Falcon, Bedford, MA, USA),
re-suspended in freezing medium (composed of 90% FBS
and 10% DMSO (sigma, St. Louis, Mo, USA)) and stored
frozen under liquid nitrogen for later use.
Tumor Tissues were digested, as stated above, for 6 hours
followed by centrifugation at 800 g for 8 minutes at 4°C.
Cell pellets were further digested with accutase for
10-15 minutes and stored frozen in liquid nitrogen.
Cell culture
Breast cancer cell lines were cultured in DMEM/F12 with
the exception of SK-BR-3, which was cultured in McCoy's
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were supplemented with 10% fetal bovine serum and
Antibiotics and Antimycotics (all from Invitrogen).
Flow cytometry
Cells were thawed, washed and, if deemed necessary, 20
to 60 μl of DNase (SCT) was added to disaggregate clumps.
Cells were depleted of CD31+ endothelial cells, whenever
necessary, using MACS system (Miltenyi Biotec, Germany),
as per manufacturer’s instructions. Cells were stained
with panels of 8 different antibodies labeled with up to 8
different fluorescent dyes in addition to 4',6-diamidino-
2-phenylindole (DAPI, Invitrogen) viability dye. The panels
and antibody combination used are listed in Tables 1 and 2
respectively. An ALDH kit (Stem Cell Technologies) was
used to stain ALDH population as per manufacture in-
structions. ALDH staining was performed first followed
by the addition of the other antibodies as recommended
by the ALDH kit.
Data were acquired using an LSR II Flow Cytometer
while a FACSAria was utilized for cell sorting (both from
BD, Biosciences, New Jersey, USA) using BD FACSDiva
operating software according to guidelines set for analysis
and sorting of stem cells by flow cytometry [12]. Positive
staining was considered based on the negativity of an isotype
control. A minimum of 10,000 events were recorded for
all samples. Most phenotypic data were validated using
the same antibodies with alternate labels.
Gating strategy
We adopted a gating strategy to analyze single viable epi-
thelial mammary cells. To this end, gates were established
to exclude debris (using FSC and SSC) and hemato-
poietic cells (by gating on CD45neg cells) and include
only single viable cells (using the relation between FSC-A
and FSC-W followed by gating on DAPIneg cells). Gated
cells were then examined with Ep-CAM and CD49f anti-
bodies followed by a final gate to select stem/progenitorTable 1 The panels of antibodies used to analyze the breast c
Label Panel 1
(Ep-CAMlow)









* Replaced with ALDH, CD31-FITC or others. ♦ Replaced in some experiments with
with SSEA-4 in some experiments.cells within each Ep-CAM/CD49f epithelial cell frac-
tion. An example of the sequential gating is present in
Additional file 1: Figure S1. ALDHhigh positivity was
selected based on staining parallel cells with DEAB in-
hibitor of ALDH activity (Additional file 2: Figure S2).
Positivity for antibodies like CD44 and CD24 (as shown
by the quadrant) was identified using isotype control
(Additional file 2: Figure S2). CD44high expression level
was selected arbitrarily to include cells having fluores-
cence intensity (FI) units greater than 3000 FI (i.e. 2 minor
ticks above 103 FI). Similarly, CD24low expression level
was set to include cells having FI lower than 3000. Using
these criteria we compared the abundance of CD44high/
CD24low cells in Ep-CAMhigh or Ep-CAMlow populations.
Due to lower expression of CD44 in luminal cells, com-
pared with basal cells, we used the relative CD44high/
CD24low of Ep-CAMhigh/CD49f + cells during sorting and
in functional assays (to obtain enough cells) and com-
pared them with the bulk of Ep-CAMhigh/CD49f + cells
(CD44high expression levels were identified as cells with
only 1 tick above 103 FI i.e. 2000 FI). This increased the
CD44high/CD24low fraction of luminal Ep-CAMhigh/
CD49f + cells from an average of 7% to 23%.
Primary breast cancer single viable cells were selected
as above. In addition, lineage negative were selected using
the CD10neg, CD31neg, and CD45neg phenotypes and after
excluding Ep-CAMneg/CD49fneg mesenchymal cell fraction.
As a quality control, expression patterns were always
cross referenced with known phenotypic data of breast cells
subsets (e.g. basal and mesenchymal cells are CD24neg [13],
mesenchymal cells are Ep-CAMneg/CD49fneg/MUC-1neg)
This assured that our gating strategy was accurate.
Immunohistochemistry
Routine immunohistochemistry of formalin-fixed, paraffin-
embedded breast cancer samples were evaluated for Her2,
estrogen receptor, and progesterone receptor status as
reported previously [14].ells
Panel 2 Panel 3 Panel 4







MUC-1 CXCR-4 ♦ CD10
Ep-CAM Ep-CAM Ep-CAM
CD44 CD31 CD44
c-kit (CD117) ♣Replaced with EPCR (CD201) in some experiments, || replaced
Table 2 Source, clone and dilution of Primary antibodies
Antibody Company clone Added volume (per 1-6 x 10^6 cells) or dilution
1 CD45-AC BD 2D1 5 μL
2 MUC-1-FITC BD HMPV 5 μL
3 CD31-FITC BD WM59 5 μL
4 CD49f-PE, FITC, PE-Cy5 BD GoH3 7 μL
5 EPCR (CD201) PE BD RCE-252 5 μL
6 SSEA-4-Percp-Cy5.5 Ebioscience 5E10 20 μL
7 ABCG2-Percp-Cy5.5 or APC Biolegend 5D3 3 μL
8 CD24-PE-Alex 610 Invitrogen SN3 5 μL
9 CD24 FITC, or PE BD ML5 5 μL
10 CD10-PE-Cy7 BD HI10a 5 μL
11 CD117 (c-Kit)-PE-Cy7 Biolegend 104D2 5 μ
12 CXCR-4 (CD184) PE-Cy7 Biolegend 12G5 5 μ
13 Ep-CAM-APC, FITC, or PE Miltenyi Biotec HEA-125 7 μL
14 CD44-APC-Cy7 Biolegend IM7 1 μL
15 CD31-Alex 760 Invitrogen WM59 1 μL
16 Estrogen alpha-unlabelled Abcam polyclonal 1/300 dilution
* Indirectly labeled with secondary anti-rabbit pacific blue antibody.
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tached to glass slides and stained as described previously
[15]. Briefly, cells were cytospin to glass slides by centri-
fugation at 800 rpm for 3 min. Slides were then air-
dried overnight, acetone fixed for 15 min and stored
at -80 C until stained. For staining, the cell membrane
was permeabilized with 0.5% triton-X (Sigma) followed
by overnight incubation with primary antibodies. After
washing, Envision + polymer (ready to use; Dako) was
used as a secondary antibody. Color was developed with
3,3′-diaminobenzidine (DAB) and instant hematoxylin
(Shandon) was used for counterstaining.
Quantification of estrogen receptor (ER) positive cells,
in normal sorted epithelial breast cells, was achieved by
counting the number of ER + cells in several high magni-
fication (x500) fields. The percentage was obtained by
dividing the number of estrogen receptor positive cells
by the total number of cells examined.
Mammosphere formation assay
Cells were seeded in ultra-low attachment plates (Corning,
Tewksbury, MA, USA) at a density of 1000 viable cells/
well in 96-well plate in 120 μL/well of medium composed
of DMEM/F12 medium supplemented with epidermal
growth factor (20 ng/mL), hydrocortisone, (500 ng/mL),
and Insulin (5 μg/mL), (all from Sigma) as well as B27
(1:50) and antibiotic/antimycotics (1:100) from Invitrogen
(Grand Island, NY, USA) [9].In addition to counting the number of mammospheres
formed, we also measured the size of mammospheres by
summing the volume (calculated as =4/3*π*r3 where r =
radius of each mammosphere) of all formed mammospheres
per cell group. This enabled us to assess the progenitor abil-
ity of the cells and to minimize the effect of mammosphere
aggregation. Results are displayed as total sphere volume in
microns3 or, where possible, mammosphere formation was
normalized to the total mammosphere size of one of the
Ep-CAM/CD49f main cell populations (i.e. Ep-CAMlow/
CD49f+, Ep-CAMhigh/CD49f + cells).
Colony formation assay
Sorted cells were cultured at a density of 300 to
500 cells/cm2 on irradiated NIH 3T3 mouse cells seeded
1 day prior at a density of 50,000 cells/cm2. Cells were
cultured in serum containing (2%) Ep-Wang medium [16]
for 24 hours followed by medium exchange to serum free
medium (Ep-sfm) [15]. Similar experiments utilizing
Epi-Cult B medium (SCT) revealed comparable data. At
the end of the experiment, colonies were counted under
phase contrast microscope or directly after fixation with
4% PFA and staining with Giemsa (Fisher Scientific).
Mouse xenotransplantation studies
All animal work, including anesthesia and euthanasia, was
done in accordance to protocols approved by the Animal
Care and Use Committee (ACUC) of KFSH&RC. Sorted
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in 50 uL FBS, mixed (1:1) with matrigel (BD Biosciences)
and injected subcutaneously (MDA-MB-468).
Statistical analysis
Significance in expression or mammosphere formation
was determined by T-test using Excel software. P < 0.05
was used to indicate significance. Correlation coefficient
was also calculated using Excel software. Error bars are
presented as standard error of the mean (SEM).
Results
In this study we used the Ep-CAM/CD49f antibody com-
bination as a common reference to correlate CSC with
normal stem/progenitors. We have characterized the
normal breast Ep-CAM/CD49f epithelial fractions and
their subpopulations then compared them with breast
cancer cells.
Breast epithelial stem/progenitor cells are limited to
CD49f + cell fractions
At First, we have re-established the stem/progenitor
ability of the Ep-CAM/CD49f cell populations. After
exclusion of stromal cells, Ep-CAM/CD49f staining
displayed three distinct epithelial cell populations des-
ignated here for simplicity as A,B and C: Ep-CAM-/low/
CD49f + (A), Ep-CAMhigh/CD49f + (B), and Ep-CAMhigh/
CD49fneg (C) (Figure 1A). Epithelial cell fractions were
sorted and their stem/progenitor cell features were
assessed using mammosphere and colony forming assays.
Figure 1B shows that population A (Ep-CAM-/low/CD49f +
cells) were the most efficient in forming mammospheres,
consistent with being the source of mammary stem cells,
followed by population B (Ep-CAMhigh/CD49f + cells). On
the other hand, population C (Ep-CAMhigh/CD49fneg)
cells did not form mammospheres. Consistently, in col-
ony forming assays, population C did not form coloniesFigure 1 Breast epithelial stem/progenitor cells are limited to CD49
Ep-CAM/CD49f epithelial cell populations (designated as A, B and C) afte
hematopoietic CD45+ and endothelial CD31+) cells and as analyzed by flo
of each of the three mammary epithelial cell populations, seeded in a 96-while populations A and B gave typical basal (or mixed)
and luminal colonies respectively (Additional file 3:
Figure S3).
Altogether, these results confirm that basal Ep-CAM-/low/
CD49f + (A) and luminal progenitor Ep-CAMhigh/CD49f +
(B) cell fractions contain the stem/progenitor epithelial
cells while Ep-CAMhigh/CD49fneg (C) contain only differ-
entiated cells. Therefore, we focused thereafter on CD49f +
populations (A and B).
CD44high/CD24low epithelial cells showed the highest
progenitor ability
Previous reports have used either one or two markers to
identify stem/progenitor cells in the human mammary
gland. However, to date, the relationship between different
markers has not been well characterized. In order to link
these stem/progenitor markers together we have simul-
taneously tested their expression levels in relation to
Ep-CAM/CD49f profile using multi-parametric (up to 9
colors) cell sorting.
CD44high/CD24low phenotype within Ep-CAM-/low/CD49f + cells
(A) enriches for basal progenitors
Basal Ep-CAM-/low/CD49f + cells expressed: CD10 (57 ±
6%), CD44high/CD24low (21 ± 4%) and Ep-CAM+/MUC-1neg
(25 ± 7%), but were ALDHneg/or low (Figure 2A). In order
to relate these markers to stem/progenitor cell function
we sorted each stem/progenitor subpopulation within
the Ep-CAM-/low/CD49f + group and examined their
mammosphere and colony forming abilities (A representa-
tive gating strategy is presented in Additional file 1: Figure 1).
All three stem/progenitor cell markers were effective
in selecting for mammosphere forming cells. However,
CD44high/CD24low cells formed more mammospheres
than other subpopulations, although the difference was
not significant except between CD44high/CD24low cells
and CD10+ fractions (Figure 2B). Interestingly, whenf + cell fractions. A) A representative dot plot showing the three
r exclusion of stromal (mesenchymal Ep-CAMneg/CD49neg,
w cytometry. B) Number of mammospheres formed from 1000 cells,
well low-attachment plate for 14 days (mean ± SEM, n = 2).
Figure 2 CD44high/CD24low phenotype, within population A, enriches for basal progenitors. A) A representative dot plot showing the
expression of each stem/progenitor cell marker in the gated population A (Ep-CAM-/low/CD49f+, gated red dots) as analyzed by flow cytometry
*numbers in brackets indicates average percentage (n = 10, mean ± SEM), quadrants show positivity while rectangles show "stem/progenitor"
marker positive population. B&C) Number of mammospheres (B) and volume (C) of each stem/progenitor subpopulation within population A
compared with the remaining bulk (rest) of population A (means ± S.E.M, n = 3). D) Colony formation assay for each cell subpopulation from
population A (means ± S.E.M, n = 2). Data in B, C and D were normalized to unfractionated population A (Ep-CAM-/low/CD49f+), **indicate
statistical significance (p < 0.05). ALL = the subpopulation within population A that express all the three stem/progenitor
markers simultaneously.
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[9], was considered, CD44high/CD24low formed significantly
larger mammospheres than the other stem/progenitor
subpopulations of Ep-CAM-/low/CD49f cells (Figure 2C).
Consistently, colony forming assays showed cells with the
CD44high/CD24low phenotype have the highest number
of basal (or mixed) colonies, while CD10neg formed the
lowest number of these colonies within the Ep-CAMlow/
CD49f + cell population (Figure 2D). Cells expressing all
three stem/progenitor cell markers simultaneously (ALL)
within Ep-CAM-/low/CD49f + cells did not form more
mammospheres or colonies than CD44high/CD24low cellssuggesting that CD44high/CD24low phenotype was accurate
enough to select for basal progenitors (Figure 2C&2D).
These data indicate that within the basal Ep-CAM-/low/
CD49f + (A) population, CD44high/CD24low cells have the
highest progenitor ability while, CD10neg cells have the least
progenitor ability (i.e. differentiated myoepithelial cells).
CD44high/CD24low phenotype within Ep-CAMhigh/CD49f + cells
(B) selects for luminal progenitors
Luminal Ep-CAMhigh/CD49f + (B) cells expressed: ALDHHigh
(34 ± 4%), CD44high/CD24low (7 ± 1%) and Ep-CAMhigh/
MUC-1neg (67 ± 5%) markers, while cells in this population
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marker(s) positive subsets, within the main Ep-CAMhigh/
CD49f + population, were sorted to evaluate their mammo-
sphere and colony forming abilities. Results show that
cells with ALL followed by cells with CD44high/CD24low
phenotype demonstrated the highest mammosphere
forming ability when both the number (Figure 3B) and
the size of mammospheres were considered (Figure 3C),
while ALDHneg/low showed the least ability to form
mammospheres or colonies (Figure 3B&C). Likewise,
ALL and CD44high/CD24low cells gave the highest per-
centages of colony forming cells (almost all luminal),Figure 3 CD44high/CD24low phenotype, within population B, selects lu
expression of each stem/progenitor cell marker in population B (Ep-CAMhig
*numbers in brackets indicates average percentage (n = 10, mean ± SEM). Q
marker positive population. B&C) Mammosphere formation measured by e
subpopulation, compared with the remaining bulk (rest) of population B (m
subpopulation from population B (means ± S.E.M, n = 2). Data in B, C & D a
significance (p < 0.05). E) Top) Representative image (x400,) of immunohisto
subpopulation of population B compared with population C (Ep-CAMhigh/C
was used as a counterstain. Bottom) Quantification of estrogen receptor po
subpopulation within population B that express all the three stem/progenialthough the difference was not statistically significant
from other subpopulations (Figure 3C).
This demonstrates that luminal cells having the CD44high/
CD24low phenotype have the highest progenitor ability
when used in combination with CD49f expression status.
CD44high/CD24low cells within Ep-CAMhigh/CD49f +
population correlates with ER negative status
Luminal mammary epithelial cells have a population of
estrogen receptor (ER) positive cells that become the
majority in hormone receptor positive breast cancers.
On the other hand, in the normal breast, proliferatingminal progenitors. A) A representative dot plot showing the
h/CD49f + population,gated red dots) as analyzed by flow cytometry,
uadrants show positivity while rectangles show "stem/progenitor"
ither number (b) or volume (C) of each stem/progenitor
eans ± S.E.M, n = 3). D) Number of colonies formed of each cell
re normalized to unfractionated population B, **indicate statistical
chemistry for estrogen receptor (nuclear, brown) in each cell
D49fneg) cells as a positive control. Gills hematoxylin (nuclear, blue)
sitive cells in each subpopulation of population B. ALL = the
tor markers simultaneously.
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fore, in order to identify these ER negative cells (pre-
sumably proliferating progenitor cells) we investigated the
ER status of cells expressing stem/progenitor cell
markers within the luminal Ep-CAMhigh/CD49f + (B)
population. Immunohistochemistry of sorted cells re-
vealed that within population B, cells with CD44high/
CD24low phenotype had the lowest number of ER positive
cells, consistent with their progenitor ability (Figure 3E).
Cells from Ep-CAMhigh/CD49fneg population (population
C), known to have the highest percentage of ER positive
cells, were used as a positive control while cells from the
Ep-CAM-/low/CD49f + population were used as a negative
control [11]. These data show correlation between CD44high/
CD24low and estrogen receptor negativity in normal mam-
mary epithelial cells within Ep-CAMhigh/CD49f + cells (B),
which is consistent with their progenitor ability.
CD44high/CD24low epithelial cells within Ep-CAMlhigh/CD49fneg
cells (population C) lack stem/progenitor ability
Finally, we measured the expression level of the breast
stem/progenitor cell markers in the Ep-CAMhigh/CD49fneg
cell population (C). Both CD44high/CD24low and Ep-CAM+/
MUC-1neg phenotypes were expressed at 11 ± 3% and
16 ± 3% respectively (Additional file 4: Figure S4). On
the other hand, there were neither ALDHhigh (majority
of cells were ALDHlow) nor CD10+ cells in this popula-
tion. Even though Ep-CAMhigh/CD49fneg cells expressed
CD44high/CD24low and Ep-CAM+/MUC-1neg markers,
they did not form mammospheres or colonies in vitro.
This emphasizes that CD44high/CD24low and Ep-CAM+/
MUC-1neg, previously described stem/progenitor markers,
could not select for progenitor cells when used alone,
and that they should to be used in combination with
Ep-CAM/CD49f profile.
These results altogether, demonstrate that there are
multiple subpopulations of progenitor cells within each
Ep-CAM/CD49f cell group. The CD44high/CD24low cells
in both basal and luminal CD49f + fractions had the
highest progenitor ability in each cell type respectively.
Ep-CAMhigh/CD49fneg, although expressing some of the
stem/progenitor cell markers, were differentiated cells as
they failed to form colonies and mammospheres in vitro





Ep-CAMneg/CD49fneg Mesenchymal √ √
Ep-CAMhigh/CD49fneg Luminal NO NO
Ep-CAMhigh/CD49f+ Luminal √ √
Ep-CAMlow/CD49f+ Myoepithelial √ √Other “stem/progenitor” cell markers do not show any
stem/progenitor enrichment ability over CD49f + cells
Besides the above examined common breast stem/
progenitor cell markers, we evaluated additional markers
that have been associated with stem/progenitor cells in
the breast (CD133, CXCR-4, SSEA-4, c-kit, EPCR, ABCB1
and ABCG2), within the Ep-CAM and CD49f cell frac-
tions. All the examined stem/progenitor cell markers
were expressed by Ep-CAMhigh/CD49f + luminal pro-
genitor cells, or Ep-CAM-/low/CD49f + basal cells. Func-
tionally, none of these markers could further enrich for
stem/progenitor cells over the main Ep-CAMlow/CD49f +
basal or Ep-CAMhigh/CD49f + luminal populations, as
assessed by mammosphere formation (Additional file 5:
Figure S5) and colony forming assays (data not shown).
This indicates that these putative stem/progenitor cell
markers did not enrich for stem/progenitor cells above
CD49f + alone.Cancer stem cells can best be enriched using combination
of CD44high/CD24low and Ep-CAMhigh/CD49+ markers
Subsequently, we sought to compare the stem/progenitor
cell populations between normal mammary epithelial cells
and breast cancer cells.The majority of breast cancer cells have luminal phenotype
While the standard profile for normal human mammary
epithelial cells depends on the expression of Ep-CAM
and CD49f, such data is currently not available for breast
cancer cells. Therefore, we compared the Ep-CAM/CD49f
expression patterns of normal mammary epithelial cells
with primary tumor cells obtained from breast cancer
patients. Our results show a clear drift in primary breast
cancer cells towards population C (Ep-CAMhigh/CD49fneg),
which almost doubled, while population A (Ep-CAM-/low/
CD49f+) decreased dramatically in cancer cells - to less
than one fourth of its normal counterpart (Figure 4A). As
population A was barely present among the breast cancer
cells, and existed in few patient samples, we focused on
population B and C (i.e. Ep-CAMhigh/CD49f + and Ep-
CAMhigh/CD49fneg respectively) as they constituted the
vast majority, if not all, of the tumor cells in primary
breast cancer samples.he stem/progenitor cell markers they express
colony
ing cells
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Figure 4 CSC are abundant in primary CD44high/CD24low/Ep-CAMhigh/CD49+ cancer cells. A) Representative dot plots for Ep-CAM/CD49f
profile of tumor cells from different breast cancer patients as analyzed by flow cytometry (top) and histogram showing percentage of each
Ep-CAM/CD49f population (n = 9 for normal breast and n = 13 for breast cancer samples). Lineage negative (CD45neg, CD10neg, CD31neg) cancer cells
were gated followed by exclusion (gating out) of Ep-CAMneg/CD49fneg mesenchymal fraction. Numbers in the corners indicate percentage of cells in
each quadrant. B) Expression level of each of the studied stem/progenitor cell markers in Ep-CAMhigh/CD49fneg and Ep-CAMhigh/CD49f + cell
fractions in 16 breast cancer patients gated as in A. C) Percentage of CD44high/CD24low/Ep-CAMhigh cancer cells (top) and after fractionation
into CD49fneg or CD49f + cells (bottom). Cases were stratified to four subtypes of breast cancers based on their estrogen receptor (ER), progesterone
receptor (PR) status, as well as overexpression of Her2 as following: ER = ER+/PR+/Her2neg, ER/Her2 = ER+/PR+/Her2+, Her2 = ERneg/PRneg/Her2+, and
basal = ERneg/PRneg/Her2neg, D&E) Mammosphere formation, measured by either number (D) or size (E) of tumor cells sorted for the stem/progenitor
markers CD44high/CD24low or ALDHhigh and expressed within Ep-CAMhigh/CD49fneg or Ep-CAMhigh/CD49f + breast cancer cell subpopulations
(means ± S.E.M, n = 7). **indicates statistical significance.
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progenitor markers
We examined more closely the expression of the stem/
progenitor cell markers in population C (Ep-CAMhigh/
CD49fneg) and population B (Ep-CAMhigh/CD49f+) of
tumor cells. We found no significant difference in the
percentage of CD44high/CD24low tumor cells among
population C (Ep-CAMhigh/CD49fneg) and population B
(Ep-CAMhigh/CD49f+) (Figure 4B). In contrast, the vast
majority of ALDHhigh cells were among the CD49f +
stained cells. This clearly shows a phenotypic similarity
in the distribution of stem/progenitor cell markers betweenprimary breast cancer cells and normal epithelial cells.
In contrast, unlike normal epithelial cells, there was no
statistically significant difference in the percentage of
Ep-CAM+/MUC-1neg cells between Ep-CAMhigh/CD49fneg
and Ep-CAMhigh/CD49f + cells, implying an alteration in
the MUC-1 expression upon carcinogenesis (Figure 4B).
We further stratified the 16 breast cancer samples analyzed
into the four main subtypes of breast cancer: ER (luminal
A), ER/Her2 (luminal B), Her2 and Basal. There was no
statistically significant difference in the expression of the
stem/progenitor markers between the four types of
breast cancer, probably due the small number of samples
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sample size, there was significant difference (P = 0.01) in
CD44high/CD24low expression among Ep-CAMhigh breast
cancer cells between ER and Basal subtypes of breast
cancer. This difference was only present among CD49f +
cancer cells (Figure 4C). This suggests that CD49f, if
used in combination, with CD44high/CD24low might be
able to link stem/progenitor cell markers with breast
cancer subtypes.
Cancer stem cells are abundant in primary CD44high/
CD24low/Ep-CAMhigh/CD49+ cancer cells
We then functionally tested the stem/progenitor cell abil-
ity of the above examined subpopulations. We assessed
the mammosphere formation of sorted CD44high/CD24low
or ALDHhigh cells that were further fractionated from
either population C (Ep-CAMhigh/CD49fneg) or population
B (Ep-CAMhigh/CD49f+) cancer cells. Stem/progenitor
cell subpopulations within CD49f + fractions of cancer
cells formed more mammospheres than their CD49fneg
cell counterparts (Figure 4D). In addition the size of the
mammospheres formed in CD49f + cancer cells were con-
siderably larger than CD49fneg cancer cells (Figure 4E).
The CD44high/CD24low cancer cells tended to form more
mammospheres than ALDHhigh-although the difference
was not statistically significant. This demonstrates that
CSC can best be enriched by selecting for tumor cells
with the CD44high/CD24low or ALDHhigh phenotypes within
Ep-CAMhigh/CD49f + cancer cells.
Breast cancer cell lines are mostly Ep-CAMhigh/CD49+
Breast cancer cell lines are frequently used as a model to
study breast cancer cells. Therefore, we have examined
the phenotype of 9 commonly used breast cancer cell lines
using the Ep-CAM/CD49f reference markers. Interest-
ingly, similar to primary breast cancer cells 6 out of 9 cell
lines had the Ep-CAMhigh luminal phenotype (Additional
file 6: Figure S6A). We then examined the expression
levels of the stem/progenitor cell markers in these cell
lines. Importantly, there was a correlation between the
percentage of cells with CD44high/CD24low phenotype
and ER negativity status (correlation coefficient 0.63)
(Additional file 6: Figure S6B).
Among all tested cell lines: MDA-MB-468 remarkably
expressed the four major stem/progenitor cell markers
previously examined i.e. CD44high/CD24low, ALDHhigh,
Ep-CAM+/MUC-1neg and CD10 (Additional file 6:
Figure S6B). We therefore decided to use this cell line as
a model to compare the four stem/progenitor markers.
We sorted then injected low cell numbers from each
stem/progenitor subpopulation of MDA-MB-468 cells
into NOD/SCID mice. After 4 weeks only CD44high/
CD24low and ALDHhigh cells formed tumors (in 4/4 of
the injected mice). This shows that CD44high/CD24lowwere comparable to ALDHhigh in enriching for cancer
stem cells in breast cancer cell lines.
These results collectively show that CD44high/CD24low
were comparable to ALDHhigh phenotype in selecting for
cancer stem cells both in primary, as well as established
breast cancer cell lines. However, while these stem cell
markers can be used alone in cell lines (vast majority are
CD49f+), the primary CD44high/CD24low breast cancer
cells existed in both CD49fneg and CD49f + cancer cell
fractions. Therefore, in primary breast cancer samples,
stem cell markers should be used in combination with
Ep-CAM/CD49f antibodies.
Discussion
The presence of stem/progenitor cell populations in the
human breast has been well documented in several re-
ports [8,9,18,19]. Several markers have been used to
identify this population including Ep-CAM-/low/CD49f +
[8], ALDH + [6], CD44high/CD24low [20], CD10+ [7], or
Ep-CAM+/MUC-1neg [9]. However, to date there is no
study with detailed comparison between these markers.
Our approach was to compare phenotypically and func-
tionally most of the previously reported stem/progenitor
cell markers side-by-side in reference to Ep-CAM/CD49f
profile. We found for the first time that CD44high/CD24low
mammary cells exhibited the highest stem/progenitor
ability, both in normal and malignant breast cells, when
combined with Ep-CAM/CD49f markers. We have used
multi-parametric (up to 9 colors) fluorescence-activated
cell sorting (FACS) coupled with several in vitro and
in vivo assays to compare the progenitor/tumorigenic
ability of the different stem/progenitor subpopulations
of the human breast. Importantly, in this study, we have
used uncultured/unmanipulated cells in contrast to sev-
eral previous reports based on cells cultured for 3 days
prior to analysis [8,10].
Since the pioneering work of Al-Hajj et al [5] on the
phenotype of CSC as CD44high/CD24low, multiple studies
have suggested that these markers did not correlated
with the survival of breast cancer patients [21-23]. We
have demonstrated in this study that CD44high/CD24low
from CD49f + cancer cells formed more mammospheres
than CD49fneg cancer cells. This indicates that it is neces-
sary to use CD49f in combination with CD44high/CD24low
panel. In agreement, Cariati et al [24] have shown that
only CD49f +MCF-7 form mammospheres and induce
tumors in mice, and not CD49fneg cells. Interestingly,
very recent clinical data (utilizing large sample size of
breast cancer patients) by Ali et al [25] have shown that
CD44high/CD24low or ALDHhigh in combination with
the CD49f positivity correlate with patient survival.
We have reported an abundance of CD44high/CD24low
in the human mammary gland of 21 ± 4% in Ep-CAMlow/
CD49f + and 7± 1% in Ep-CAMhigh/CD49f + cell populations.
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population is restricted to Ep-CAMlow/CD49f + fraction of
cells [26]. This discrepancy is most likely due to the
CD44high gating used. To our knowledge, there is no
standard criterion in the literature to describe CD44high
and CD24low gates (The criteria we used is clearly de-
scribed in the methods and materials section). However,
regardless of the gate used, we have established here
that the relative fraction CD44high/CD24low among
Ep-CAMhigh/CD49f + cell population was able to enrich
for colony forming cells more than 2 times the bulk of
Ep-CAMhigh/CD49f + cells. This indicates that the gate
for CD44high/CD24low does not have to be the same for
Ep-CAMhigh and Ep-CAMlow in order to select for epithe-
lial progenitors. This further supports the importance of
using CD44high/CD24low phenotype in combination with
Ep-CAM/CD49 reference markers.Figure 5 Similarities/differences between normal and malignant brea
summarizes the similarities and differences between the different Ep-CAM/
into subpopulations based on the expression of other stem/progenitor cel
normal breast (A, B, and C), and their subpopulations, on top are compare
epithelial population (average ± SEM, n = 9 normal & n = 12 for breast canc
mammosphere/colony forming cells. For mammosphere and colony forminIn this report, we have demonstrated that the majority
of cancer cells showed a luminal Ep-CAMhigh pheno-
type, with very small percentage of cancer cells of
Ep-CAM-/low/CD49f + phenotype. Similarly, 6 out of 9
breast cancer cell lines had Ep-CAMhigh phenotype. These
findings are consistent with the previously described
luminal phenotype of cancer cells based on strong cor-
relative evidence showing breast cancer cells express
luminal markers (such as MUC-1, Keratins 18 and 19
[27]), and lack basal markers (like CD10 and α-SMA [28]).
In addition, Ince et al [29] established that transformed
luminal cells (BPLER) were able to form tumors from as
little as 102 cells, while as many as 106 cells were needed
to form tumor from (HMLER) basal enriched transformed
cells. This indicates that luminal cells are more tumori-
genic than basal cells. In addition, Fillmore et al [13] have
shown that CD44high/CD24low within Ep-CAM+ and notst epithelial stem/progenitor subpopulations. The diagram
CD49f populations. Each epithelial population was further fractionated
l makers. The three Ep-CAM/CD49f epithelial cell populations of the
d with their malignant counterpart below. ♣Percentage of each
er).**NA = not done due to very low cell yield *Mo/CFC =
g ability, √√√ = high, √√ =medium, √ = low, X = none.
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cell features including colony formation and tumorigen-
icity in NOD/SCID mice. Unfortunately, we could not
characterize Ep-CAMlow primary cancer cells although
they are interesting population as they correspond to
the mammary stem cell enriched population in the nor-
mal mammary gland. This is because cancer cells, with
Ep-CAMlow/CD49f + phenotype, were present only in
some patients and represented small percentages mak-
ing them practically infeasible for us to study them.
The cell of origin of most of breast cancers still re-
mains unknown. Keller et al [30] have demonstrated that
transforming Ep-CAMhigh luminal cells produce breast
cancers commonly seen in the clinic, while transforming
normal mammary basal Ep-CAMlow/CD10+ cells pro-
duces a rare undifferentiated metaplastic type of breast
cancer. Our results illustrate a similarity of phenotype
between CSC and normal luminal progenitors. In addition,
the phenotype of cancer cell lines being Ep-CAMhigh/
CD49f +might further suggest the origin of CSC from
Ep-CAMhigh/CD49f + normal luminal progenitors, at least
in some cases of breast cancer. In agreement, Lim et al [11]
and Molyneux et al [31] have demonstrated that the cell
of origin of BRCA1 defective breast carcinomas, a pre-
dominantly triple negative type of breast cancer, is also in
the Ep-CAMhigh/CD49f + luminal progenitor cells. Simi-
larly, Lo et al [32] has shown the Ep-CAMhigh/CD49f +
cells are the cell of origin of Her2/neu mouse model.
On the other hand, histological observation of the
abundance of CD44high/CD24low cells in the normal basal
layer of the breast (anatomically in close contact with base-
ment membrane) [33] has encouraged others to speculate
that CD44high/CD24low cancer cells might originate from
the Ep-CAMlow normal basal layer [34]. Our results suggest
that the luminal layer might be an additional source for
CD44high/CD24low cancer cells. This is further supported
by our finding that only the luminal fraction of CD44high/
CD24low cells overlaps with ALDHhigh cells. Overall, under-
scores the importance of using stem cell markers CD44high/
CD24low in combination with Ep-CAM/CD49f.
Conclusions
In the normal human mammary gland we have validated
and compared side-by-side many breast stem/progenitor
cell markers and found that among them only ALDHhigh,
CD10+, CD44high/CD24low Ep-CAM+/MUC-1neg can en-
rich for stem/progenitor cells over CD49f + alone. CD44high/
CD24low had the highest ability to enrich for cell progenitors
when used in combination with Ep-CAM/CD49f antibodies
in order to differentiate between basal or luminal progeni-
tors. Similarly, in breast cancer CD44high/CD24low (as well
as ALDHhigh) showed the highest ability to enrich for
CSC. When normal breast stem/progenitor populations
are compared with their counterparts in breast cancer,there were similarities and differences between stem/pro-
genitor cells in normal and malignant breast. In both nor-
mal and cancer cells there was a correlation between
CD44high/CD24low phenotype and estrogen receptor nega-
tive status. In addition, there were cells with the CD44high/
CD24low phenotype in both Ep-CAMhigh/CD49f + and
Ep-CAMhigh/CD49fneg cell populations. Furthermore,
ALDH was highly expressed by Ep-CAMhigh/CD49f +
cells in both normal and malignant cells. On the other
hand, breast cancer cells had mainly luminal phenotype,
with an increase in the CD49fneg fraction compared
with normal breast which exhibited balanced popula-
tions of luminal (both differentiated and progenitor)
and basal cells. The CD49fneg cells in normal breasts
could not form mammospheres, while in malignant breast
they formed mammospheres, albeit to a much lesser extent
than CD49f + cells (summarized in Figure 5). CD44high/
CD24low is expressed by both CD49f + and CD49fneg can-
cer cells. However, CD44high/CD24low/CD49f + had sig-
nificantly higher stem/progenitor ability as measured by
mammosphere formation thus proposing that these
cells are the best phenotype to identify breast CSC.
These findings may provide a better understanding of
how CSC evolve, and which population to target and
monitor during therapy, a leading step to eradicate this
disease at its root.Additional files
Additional file 1: Figure S1. Gating strategy to analyze breast cells. Dot
plot for isolated breast cells analyzed with sequential gating starting first
with Forward scatter (FSC) and side scatter (SSC) to extract cells from
debris followed by Relation of the area under the curve of the forward
scatter signal (FSC-A) and the width of the forward scatter signal (FSC-W)
to select for single cells only. DAPI positive cells were excluded to gate
viable cells only. CD45 were used to exclude hematopoietic cells
followed by gating on the different Ep-CAM/CD49 epithelial fraction.
Finally the stem/progenitor subpopulation (Ep-CAM+/MUC-1neg, CD10+
or CD44high/CD24low) was sorted. With each stem/progenitor cells the
remaining bulk from the specific epithelial Ep-CAM/CD49f fraction was
also concomitantly sorted (identified as Rest). * Whenever necessary
CD31+ endothelial cells were depleted by MACS prior cell acquisition.
Additional file 2: Figure S2. Gating of different markers using antibody
isotype control and or DEAB inhibitor of ALDH activity. A representative
dot plot showing the background fluorescence of cells stained with
either antibody isotype control or treated with DEAB inhibitor for ALDH
activity.
Additional file 3: Figure S3. Characterization of the Ep-CAM/CD49f
four populations. A representative dot plot of normal mammary cells
showing the three main epithelial Ep-CAM/CD49f populations designated
as A, B and C in addition to the mesenchymal fraction. Sorted
populations A and B contained cells that formed (in vitro) typical basal
(myoepithelial) or luminal colonies respectively. Population C did not
form colonies while mesenchymal (Ep-CAMneg/CD49fneg) cells formed
typical mesenchymal-shaped colonies.
Additional file 4: Figure S4. Expression of Stem/progenitor cell markers
in Ep-CAMhigh/CD49fneg cells. A representative dot plot showing the
expression of each stem/progenitor cell marker in population C
(Ep-CAMhigh/CD49fneg cells) as analyzed by flow cytometry *numbers
in brackets indicates average percentage (n = 5) ± SEM.
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http://www.biomedcentral.com/1471-2407/13/289Additional file 5: Figure S5. Mammosphere formation of cells positive
for the above markers sorted from either population A (Ep-CAMlow/CD49f+,
top) or population B (Ep-CAMhigh/CD49f+, bottom) cell populations, error
bars indicates mean ± SEM (n = 2). Mammospheres formed were
normalized to unfractionated population A or B respectively.
Additional file 6: Figure S6. Stem/progenitor subpopulations in breast
cancer cell lines. A) Sketch that summarizes the Ep-CAM/CD49f profile of
9 commonly used breast cancer cell lines. B) Expression level of stem/
progenitor cell markers in breast cancer cell lines, as determined by flow
cytometry.
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